Dividend and Share Capital - The company plans to distribute a cash dividend of RMB 17.50 per 10 shares, totaling approximately RMB 169.89 million, which represents 25.24% of the net profit attributable to shareholders for 2024[5]. - The company intends to increase its share capital by 4.5 shares for every 10 shares held, resulting in an increase of approximately 43.69 million shares, raising the total share capital to approximately 140.77 million shares[5]. Financial Performance - The company reported a significant increase in revenue, reaching RMB 1.2 billion for the fiscal year 2023, representing a growth of 25% compared to the previous year[21]. - The company's operating revenue for 2024 reached ¥2,065,801,597.74, representing a 25.18% increase compared to ¥1,650,211,802.94 in 2023[22]. - Net profit attributable to shareholders for 2024 was ¥673,151,713.17, up 26.08% from ¥533,924,244.00 in 2023[22]. - The basic earnings per share for 2024 was ¥6.96, a 25.63% increase from ¥5.54 in 2023[23]. - The weighted average return on equity for 2024 was 30.35%, slightly up from 30.19% in 2023[23]. - The company's net assets attributable to shareholders grew by 31.94% to ¥2,516,339,545.43 at the end of 2024, compared to ¥1,907,142,308.67 at the end of 2023[22]. - The total assets increased by 15.85% to ¥2,980,697,768.82 at the end of 2024 from ¥2,572,982,295.44 at the end of 2023[22]. - The net cash flow from operating activities for 2024 was ¥743,390,010.98, reflecting a 7.88% increase from ¥689,058,072.49 in 2023[22]. Research and Development - The company is investing RMB 200 million in R&D for new technologies, including pulsed field ablation techniques, to enhance treatment options[21]. - Research and development expenses accounted for 14.06% of operating revenue in 2024, a slight decrease from 14.42% in 2023[24]. - The company achieved a total R&D investment of ¥290,539,080.33, representing a 22.12% increase compared to the previous year[84]. - The company filed 35 new invention patent applications and was granted 13 during the reporting period, bringing the total granted invention patents to 74[82]. - The company has a total of 440 intellectual property applications, with 229 granted, reflecting its commitment to innovation and patent protection[82]. Market Expansion and Strategy - The company provided a positive outlook for 2024, projecting a revenue growth of 30% year-over-year, aiming for RMB 1.56 billion[21]. - Market expansion plans include entering two new international markets by Q3 2024, targeting a 10% increase in global market share[21]. - The company is considering strategic acquisitions to bolster its product portfolio, with a budget of RMB 500 million allocated for potential mergers[21]. - The company plans to continue expanding its market presence and enhancing product profitability, contributing to the overall profit growth[25]. - The company aims to enhance its market penetration in the peripheral vascular field through continuous innovation and large-scale production[158]. Governance and Compliance - The company has received a standard unqualified audit report from its accounting firm, indicating the financial statements' accuracy and completeness[4]. - The company has confirmed that all board members are present for the board meeting, ensuring governance compliance[4]. - The company has established four specialized committees under the board to enhance governance and decision-making processes[170]. - The company reported no significant differences in governance practices compared to regulatory requirements[170]. - The company has not faced any objections from board members regarding company matters during the reporting period[195]. Operational Efficiency - The gross margin improved to 60%, up from 55% in the previous year, due to cost optimization strategies[21]. - The company aims to enhance its supply chain efficiency, reducing operational costs by 15% in the next fiscal year[21]. - The company has improved its internal control systems and governance structure to enhance operational efficiency and safeguard shareholder interests[43]. - The company is focusing on optimizing production processes and enhancing automation to reduce costs and improve efficiency[126]. User Growth and Engagement - User data showed an increase in active users by 15%, totaling 3 million active users by the end of 2023[21]. - User data indicates a 20% increase in active users, reaching a total of 1.5 million users[179]. - User data showed a growth of 25% in active users, totaling 5 million by the end of the quarter[180]. Product Development and Launches - New product launches are expected to contribute an additional RMB 300 million in revenue in 2024, focusing on advanced cardiac devices[21]. - The company launched new electrophysiological products, including AForcePlusTM catheter and PulstamperTM catheter, marking its entry into the atrial fibrillation treatment market[37]. - The company is set to launch three new products in Q2 2024, which are anticipated to contribute an additional $50 million in revenue[179]. Risks and Challenges - The company faces risks related to market competition and potential price declines due to industry policies, necessitating continuous innovation and strategic adjustments[109]. - The company is exposed to macroeconomic risks, including currency depreciation in key markets and rising logistics costs due to geopolitical tensions[115]. - The company faces potential risks related to product quality and regulatory compliance, particularly for Class III medical devices[113]. Compensation and Remuneration - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to RMB 1,682.79 million[188]. - The total remuneration for core technical personnel at the end of the reporting period amounted to RMB 391.83 million[188]. - The remuneration for independent directors is set at RMB 18 million as a stipend[187]. - The total pre-tax compensation for all executives in the reporting period amounted to 1,812.02 million CNY[177]. Future Outlook - The company aims to become a world-leading high-tech firm in the electrophysiology and vascular intervention fields, focusing on continuous investment in R&D and innovation[159]. - The company plans to enhance its market share in the domestic electrophysiology and vascular access markets by leveraging its product advantages and marketing synergies with its medical team[160]. - Future guidance indicates a strong focus on digital transformation and telemedicine solutions, aiming for a 40% increase in digital service revenue by 2025[179].

Financial Performance - The company's operating revenue for Q1 2025 was CNY 564,276,710.67, representing a year-on-year increase of 23.93% compared to CNY 455,327,284.53 in the same period last year[4] - The net profit attributable to shareholders for Q1 2025 was CNY 183,151,687.90, reflecting a growth of 30.69% from CNY 140,143,827.76 in the previous year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 180,530,401.14, up 32.23% from CNY 136,530,234.33 year-on-year[4] - The basic earnings per share for Q1 2025 were CNY 1.89, an increase of 30.34% compared to CNY 1.45 in the previous year[4] - The diluted earnings per share rose by 30.56% to CNY 1.88 from CNY 1.44 year-on-year[4] - Total operating revenue for Q1 2025 reached CNY 564.28 million, a 24% increase from CNY 455.33 million in Q1 2024[16] - Net profit for Q1 2025 was CNY 180.14 million, representing a 31% increase compared to CNY 137.86 million in Q1 2024[17] Cash Flow - The net cash flow from operating activities increased by 45.45%, reaching CNY 166,662,587.49 compared to CNY 114,587,998.06 in the same period last year[4] - In Q1 2025, the cash inflow from operating activities was $661.67 million, a 28.2% increase from $516.00 million in Q1 2024[19] - The net cash flow from operating activities for Q1 2025 was $166.66 million, up 45.5% from $114.59 million in Q1 2024[19] - The cash inflow from operating activities included $634.32 million from sales, up from $506.83 million in the previous year[19] - The total cash outflow from operating activities in Q1 2025 was $495.00 million, compared to $401.42 million in Q1 2024[19] - The company experienced a net increase in cash and cash equivalents of $116.59 million in Q1 2025, contrasting with a decrease of $622.21 million in Q1 2024[20] - The company reported a cash inflow from tax refunds of $5.67 million in Q1 2025, up from $3.78 million in Q1 2024[19] Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,144,592,769.23, a 5.50% increase from CNY 2,980,697,768.82 at the end of the previous year[5] - The company's total liabilities decreased to CNY 408.14 million as of March 31, 2025, from CNY 425.85 million as of December 31, 2024[14] - The total equity attributable to shareholders increased by 7.34% to CNY 2,700,953,801.47 from CNY 2,516,339,545.43 at the end of the previous year[5] - The company's total liabilities were not specified, but accounts payable increased to RMB 53,939,696.98 from RMB 46,315,037.80, indicating a rise of approximately 16.5%[12] - The company's current assets totaled RMB 1,750,830,787.65, up from RMB 1,616,687,606.56, indicating an increase of about 8.3%[12] - The cash and cash equivalents amounted to RMB 1,197,674,280.85, compared to RMB 1,081,087,911.03 in the previous period, representing a growth of approximately 10.8%[11] Research and Development - Research and development expenses totaled CNY 73,969,533.27, which is a 12.73% increase from CNY 65,615,307.81 in the same period last year[4] - The proportion of R&D expenses to operating revenue decreased to 13.11% from 14.41% year-on-year, a reduction of 1.30 percentage points[4] - Research and development expenses for Q1 2025 were CNY 73.97 million, an increase from CNY 65.62 million in Q1 2024[16] Strategic Direction - The company is focusing on expanding its market presence and enhancing its product offerings, although specific new products or technologies were not detailed in the provided content[10] - The company has not disclosed any significant mergers or acquisitions during the reporting period, maintaining its current strategic direction[10]

证券代码：688617 证券简称： 惠泰医疗 公告编号：2025-013 深圳惠泰医疗器械股份有限公司 第二届董事会第二十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳惠泰医疗器械股份有限公司（以下简称"公司"）于 2025 年 4 月 21 日以现场结合通讯表决方式召开了第二届董事会第二十一次会议，会议应到董事 9 人，实到董事 9 人，出席董事占应出席人数的 100%。本次会议的召集、召开 及表决程序符合《中华人民共和国公司法》等有关法律、行政法规、规范性文件 和《深圳惠泰医疗器械股份有限公司章程》（以下简称"《公司章程》"）的规 定，会议决议合法有效。经与会董事审议和表决，会议形成决议如下： 本议案尚需提交公司 2024 年年度股东大会审议。 一、审议通过《关于公司<2024年年度报告>及其摘要的议案》 具体内容详见公司同日在上海证券交易所网站(www.sse.com.cn)披露的《深 圳惠泰医疗器械股份有限公司 2024 年年度报告》及《深圳惠泰医疗器械股份有 限公司 2024 年年度报告摘 ...

证券代码：688617 证券简称：惠泰医疗 公告编号：2025-017 深圳惠泰医疗器械股份有限公司 关于 2024 年度利润分配及资本公积金转增股本预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （一）利润分配及资本公积金转增股本预案的内容 经立信会计师事务所（特殊普通合伙）审计，深圳惠泰医疗器械股份有限公 司（以下简称"公司"）2024 年度合并报表归属于上市公司股东的净利润为人 民币 673,151,713.17 元。截至 2024 年 12 月 31 日，母公司期末可供分配利润为 270,292,245.53 元。 重要内容提示： 每股分配及转增比例：每 10 股派发人民币现金红利 17.50 元（含税）， 同时以资本公积金向全体股东每 10 股转增 4.5 股。 本次利润分配及资本公积金转增股本以实施权益分派股权登记日登记的 总股本为基数，具体日期将在权益分派实施公告中明确。 在实施权益分派的股权登记日前公司总股本发生变动的，公司拟维持每 股分配及转增比例不变，相应调整分配总额及转增股本总额，并将另行 ...

深圳惠泰医疗器械股份有限公司 审计报告及财务报表 二○二四年度 深圳惠泰医疗器械股份有限公司 审计报告及财务报表 （2024 年 01 月 01 日至 2024 年 12 月 31 日止） | | 目录 | 页次 | | --- | --- | --- | | 一、 | 审计报告 | 1-5 | | 二、 | 财务报表 | | | | 合并资产负债表和母公司资产负债表 | 1-4 | | | 合并利润表和母公司利润表 | 5-6 | | | 合并现金流量表和母公司现金流量表 | 7-8 | | | 合并所有者权益变动表和母公司所有者权益变动表 | 9-12 | | | 财务报表附注 | 1-124 | 审 计 报 告 信会师报字[2025]第 ZA11468 号 深圳惠泰医疗器械股份有限公司全体股东： 一、 审计意见 我们审计了深圳惠泰医疗器械股份有限公司（以下简称惠泰医疗） 财务报表，包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公 司所有者权益变动表以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会 ...

智通财经4月22日电，惠泰医疗(688617.SH)公告称，2025年第一季度营业收入5.64亿元，同比增长 23.93%；归属于上市公司股东的净利润1.83亿元，同比增长30.69%。基本每股收益1.89元。 惠泰医疗：第一季度净利润同比增长30.69% ...

从指数持仓来看，中证全指医疗行业指数十大权重分别为：迈瑞医疗（14.15%）、爱尔眼科 （8.89%）、联影医疗（7.82%）、爱美客（4.05%）、惠泰医疗（4.0%）、鱼跃医疗（3.12%）、上海 医药（3.09%）、新产业（3.03%）、益丰药房（2.65%）、美年健康（2.5%）。 金融界4月22日消息，A股三大指数收盘涨跌不一，中证全指医疗行业指数 (医疗行业，932131)报537.08 点。 数据统计显示，中证全指医疗行业指数近一个月下跌5.24%，近三个月下跌0.28%，年至今下跌5.24%。 据了解，中证全指行业优选指数系列从中证全指行业中选取符合一定流动性与市值筛选条件的上市公司 作为指数样本，以反映各个行业内较具代表性与可投资性的上市公司证券的整体表现。该指数以2021年 12月31日为基日，以1000.0点为基点。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在下一个定期 调整日前，权重因子一般固定不变。遇临时调整时，当中证全指指数调整样本时，中证全指行业指数 ...

Core Viewpoint - The China Securities Index for Healthcare Equipment and Services has shown a recent increase, but it has experienced declines over the past month, three months, and year-to-date [1]. Group 1: Index Performance - The CSI Healthcare Equipment and Services Index rose by 1.17% to 13,221.28 points with a trading volume of 10.971 billion [1]. - Over the past month, the index has decreased by 9.68%, by 0.46% over the last three months, and by 4.54% year-to-date [1]. Group 2: Index Composition - The index is composed of listed companies in the healthcare sector, reflecting the overall performance of these securities [1]. - The top ten weighted companies in the index include Mindray Medical (9.26%), Aier Eye Hospital (8.31%), and United Imaging Healthcare (7.36%) [1]. - The index's holdings are primarily from the Shenzhen Stock Exchange (60.12%) and the Shanghai Stock Exchange (39.88%) [1]. Group 3: Fund Tracking - Public funds tracking the healthcare index include several funds such as Southern CSI Healthcare Equipment and Services Link A, Tianhong CSI Healthcare Equipment and Services ETF, and others [2].

4月21日，惠泰医疗今日收盘438.5元，上涨1.31%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到63.21倍，总市值425.70亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均47.69倍，行业中值29.88倍，惠泰医疗排 名第97位。 截至2024年三季报，共有40家机构持仓惠泰医疗，其中基金40家，合计持股数471.21万股，持股市值 18.25亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)97惠泰医疗63.2163.2117.83425.70亿行业平均 47.6950.834.76102.51亿行业中值29.8830.502.3545.38亿1天益医疗-2712.97-2712.971.7020.18亿2硕世生 物-1868.25-1868.251.1537.40亿3诺唯赞-536.80-536.802.4697.13亿4澳华内镜-516.11258.864.1354.39亿5博 晖创新-360.85-222.173.9855.39亿6康泰医学-265.2731.122.7151.59亿7华大基因-198.26216.862.05201.47亿 8奥精 ...